Recent developments highlight Tango Therapeutics' clinical progress and strategic initiatives, including new trial enrollments, positive pancreatic cancer trial results, workforce adjustments, and leadership changes.

• Tango and Erasca initiated enrollment in a Phase 1/2 combination trial for pancreatic and lung cancers evaluating vopimetostat with Erasca's pan-RAS molecular glue ERAS-0015 [N1].
• The company reported an 82% response rate in a pancreatic cancer trial and is targeting a Phase III trial in 2027 based on these results [N2][N3].
• Tango announced Phase 1/2 vopimetostat trial results alongside a 14% workforce reduction in October 2026 [N4].
• The stock experienced a 6.2% decline since the last earnings report amid higher expenses and expanded net loss [N5][N6].
• The company is conducting combination clinical trials with RAS inhibitors from Revolution Medicines and others, with ongoing enrollment and early efficacy data [N1][N2].

The company has demonstrated promising clinical activity with its lead candidate vopimetostat in MTAP-deleted pancreatic cancer, showing meaningful progression free survival and response rates. Ongoing combination trials with RAS inhibitors and other agents may enhance therapeutic efficacy and broaden indications. Tango's strong liquidity position supports continued development and potential expansion of its pipeline. Collaborations with other biotech firms provide access to complementary therapies and resources. Positive clinical data and successful trial execution could validate its precision oncology approach and support future growth opportunities.

Tango Therapeutics faces risks inherent to clinical-stage biotech companies, including the uncertainty of clinical trial outcomes and regulatory approvals. The company's reliance on third-party drugs for combination therapies introduces supply and cost risks that could delay development timelines or increase expenses. The absence of approved products means ongoing operating losses and the need for substantial additional funding, which may not be available on favorable terms. Workforce reductions and market reactions to trial results indicate operational and market challenges. Failure to secure necessary capital or clinical supply could materially impact the company's prospects.

Tango Therapeutics' moat is based on its proprietary target and drug discovery platforms that enable the identification of novel, genetically defined cancer vulnerabilities and the development of selective small molecule therapies. Its focus on MTAP-deleted cancers and precision oncology approaches targeting specific genetic alterations provides a differentiated pipeline. Collaborations with established biotech firms for combination trials and a robust clinical development program further support its competitive positioning. However, as a clinical-stage company without approved products, its moat depends on successful clinical development and regulatory approvals.

• Clinical Development Risk: The success of Tango's product candidates depends on positive clinical trial outcomes, which are inherently uncertain and may not lead to regulatory approval.
• Dependence on Third-Party Drugs: Combination therapies rely on access to third-party drugs, and any failure to secure supply on reasonable terms could delay development or increase costs.
• Financial Risk: The company has incurred significant losses and requires substantial additional funding to continue operations and advance its pipeline.
• Operational Risk: Recent workforce reductions and management changes may impact operational efficiency and execution.
• Market and Regulatory Risk: Regulatory approvals and market acceptance of novel targeted therapies are uncertain and may affect commercial viability.

• Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing targeted therapies in oncology by addressing specific genetic alterations driving cancer.
• The company leverages proprietary target and drug discovery platforms to identify novel disease-relevant targets and develop small molecule medicines tailored to defined patient populations with high unmet medical need.
• Tango's lead clinical programs include two MTAP-deleted selective PRMT5 inhibitors: vopimetostat (TNG462) for non-CNS cancers and TNG456, a brain-penetrant PRMT5 inhibitor for CNS cancers including glioblastoma.
• Vopimetostat is being evaluated as monotherapy and in combination with RAS inhibitors, with clinical trials ongoing including combinations with Revolution Medicines' daraxonrasib and zoldonrasib, and Erasca's pan-RAS molecular glue ERAS-0015.
• Positive Phase 1/2 clinical data for vopimetostat monotherapy in MTAP-deleted pancreatic cancer showed a median progression free survival of 7.2 months and 25% objective response rate, supporting a planned pivotal 2L trial in 2026.
• The histology selective cohort (excluding sarcoma, pancreatic, and lung cancers) showed a median progression free survival of 9.1 months and 49% objective response rate.
• Combination trials of vopimetostat with RAS inhibitors have enrolled patients with encouraging early efficacy and tolerability data.
• TNG456 is in Phase 1/2 dose escalation for MTAP-deleted solid tumors with focus on glioblastoma, with ongoing enrollment and anticipated updates in 2026.
• TNG961 is a molecular glue candidate targeting HBS1L for degradation in FOCAD-deleted/MTAP-deleted cancers, currently in IND-enabling phase.
• TNG260 is a first-in-class CoREST inhibitor in dose expansion for checkpoint inhibitor resistant STK11 mutant/KRAS wild-type NSCLC, showing median progression free survival of 29 weeks in early data.
• The company has no approved products and has not generated revenue from product sales to date.
• Tango has funded operations primarily through equity financings and collaboration agreements, including a collaboration with Gilead Sciences.
• As of September 30, 2026, Tango had cash and cash equivalents of $86.8 million, short-term investments of $890.7 million, current assets of $992.7 million, and current liabilities of $25.2 million, resulting in a current ratio of 39.45 and a cash ratio of 38.85.
• For the quarter ended September 30, 2026, the company reported a net loss of $68.4 million and basic and diluted EPS of -$0.39.
• The company completed an underwritten offering and private placement in October 2025 raising gross proceeds of $225 million, netting $211.8 million after expenses.
• Tango has entered into clinical trial collaboration and supply agreements with Revolution Medicines, Lilly, and Erasca for combination trials.
• The company announced a 14% workforce reduction in October 2026 alongside Phase 1/2 trial results for vopimetostat.
• The Board appointed Robert Azelby as Chair effective August 6, 2026.
• The company faces risks related to reliance on third-party drugs for combination therapies, potential delays or inability to secure clinical supply on reasonable terms, and the need for substantial additional funding to continue operations.
• Tango's common stock trades on Nasdaq under the ticker TNGX.
• The company has approximately 15 stockholders of record as of February 26, 2026.
• The company intends to retain all available funds and future earnings to fund development and expansion and does not expect to pay dividends in the foreseeable future.